sr 33557 has been researched along with vanoxerine in 1 studies
| Studies (sr 33557) | Trials (sr 33557) | Recent Studies (post-2010) (sr 33557) | Studies (vanoxerine) | Trials (vanoxerine) | Recent Studies (post-2010) (vanoxerine) |
|---|---|---|---|---|---|
| 50 | 3 | 1 | 556 | 5 | 93 |
| Protein | Taxonomy | sr 33557 (IC50) | vanoxerine (IC50) |
|---|---|---|---|
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.5098 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.0103 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 1.5513 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.0969 | |
| Small conductance calcium-activated potassium channel protein 2 | Rattus norvegicus (Norway rat) | 0.073 | |
| Small conductance calcium-activated potassium channel protein 3 | Rattus norvegicus (Norway rat) | 0.073 | |
| Small conductance calcium-activated potassium channel protein 1 | Rattus norvegicus (Norway rat) | 0.073 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.0424 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.022 | |
| Transporter | Rattus norvegicus (Norway rat) | 0.114 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
1 other study(ies) available for sr 33557 and vanoxerine
| Article | Year |
|---|---|
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |